Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre double-blind, randomized parallel group study to evaluate the efficacy safety and tolerability of ezetimibe/simvastatin 10/40mg, atorvastatin 40mg, and rosuvastatin 10mg to Achieve an LDL-C [low-density lipoprotein-Cholesterol] Level of less than 2mmol/L in patients with established cardio vascular disease (CVD) or at 'High Risk' of Developing CVD Currently Treated With Simvastatin 40mg and With a Fasting LDL-C 2 Mmol/L

Next Previous
Trial Profile

A multicentre double-blind, randomized parallel group study to evaluate the efficacy safety and tolerability of ezetimibe/simvastatin 10/40mg, atorvastatin 40mg, and rosuvastatin 10mg to Achieve an LDL-C [low-density lipoprotein-Cholesterol] Level of less than 2mmol/L in patients with established cardio vascular disease (CVD) or at 'High Risk' of Developing CVD Currently Treated With Simvastatin 40mg and With a Fasting LDL-C 2 Mmol/L

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ezetimibe/simvastatin (Primary) ; Atorvastatin; Rosuvastatin
  • Indications Cardiovascular disorders
  • Focus Therapeutic Use
  • Sponsors Merck & Co; Organon

    • Most Recent Events

    • 30 Jul 2019 New source Identified and Integrated as per European Clinical Trials Database (EudraCT) record.
    • 29 Aug 2009 Results presented at ESC Congress 2009: Annual Congress of the European Society of Cardiology.
    • 29 Aug 2009 Primary endpoint 'Target achievement rate' has been met, according to results presented at ESC Congress 2009: Annual Congress of the European Society of Cardiology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top